Mitsubishi Kasei Corporation

Kagoshima University

Other

Chugai Seiyaku Kabushiki Kaisha

Miyazaki Prefecture

Miyazaki Enterprise Promotion Organization

Unkai Shuzo Co., Ltd.

Minami Nippon Dairy Co-op Co., Ltd.

Miyazaki Prefectural Industrial Support Foundation

Hirohito Tsubouchi

Yasushi Daikuhara

Hirofumi Uto

Kozo Takahashi

Kazuhiro Takahashi

Naomi Kitamura

Keiji Miyazawa

Daiji Naka

Masayuki Sudo

Yoshiko Yoshiyama

Rie Matsui

Shuji Hashimoto

Miho Sakai

Hiroaki Kataoka

Takanori Kai

Hideaki Hirabaru

Hiroyuki Nakayama

Masahiko Takeshita

Ena Akamatsu

Shuichi Hirono

Eiichi Gohda

Yuga Komaki

Takeshi Okanoue

Akio Ido

Yo-ichi Ishida

Takehisa Ishii

Yuko Sato

According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Pharmaceutical composition for treating and/or preventing esophageal stenosis

This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1), 

Agent for inhibiting production of hepatitis C virus and its use

Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease.

Biomarker for diagnosis of liver disease

According to the present invention, there are provided hepatic parenchymal cell growth factor obtained by recombinant DNA technology, a gene coding for the factor, an expression vector capable of expressing the gene, a cell, in particular animal cell, transformed with the expression vector, and a process for producing the hepatic parenchymal cell growth factor.

Hepatic parenchymal cell growth factor gene encoding the same, process

A hepatocyte growth factor comprising a proteinous substance derived from human blood and showing the following physicochemical properties and physiologic activity:

Hepatocyte growth factor

Growing community of inventors

Kagoshima, Japan

Hirohito Tsubouchi